Study of JS014, Toripalimab and TACE for Untreated Liver Cancer
Part of Cancer, Digestive system clinical trials.
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed with surgery.
- You should be between 18 and 75 years old.
- You must be able to do most daily activities with little or no help (ECOG score 0 or 1).
- Your liver function must be fairly good, with a Child-Pugh score of 7 or less.
- Your cancer should not have been treated before, and at least one tumor must be measurable on a scan.
- You cannot have certain other liver cancers, severe fluid buildup in the belly, or a history of blood clots or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This study looks at combining TACE (a procedure that delivers chemotherapy directly to the liver) with two newer drugs — tislelizumab (immunotherapy) and lenvatinib (targeted therapy) — for people with advanced liver cancer. The goal is to see how well this combination works when used together.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.